News Travere claims first FDA OK in rare kidney disease FSGS Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.
News Boehringer drug scores in rare kidney disease FSGS Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.
Oncology Precision medicine takes a village, with Carolyn Sousa and H... In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.